CRIS Current Research Information System

TREVISANI, FRANCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.816
AS - Asia 14.733
EU - Europa 10.846
SA - Sud America 905
AF - Africa 784
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 9
Totale 44.123
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.613
VN - Vietnam 4.607
SG - Singapore 3.646
CN - Cina 3.287
GB - Regno Unito 2.514
IT - Italia 2.131
DE - Germania 1.308
SE - Svezia 1.069
HK - Hong Kong 1.030
FR - Francia 755
IN - India 721
BR - Brasile 647
RU - Federazione Russa 568
UA - Ucraina 551
IE - Irlanda 449
NL - Olanda 354
CH - Svizzera 266
BD - Bangladesh 264
JP - Giappone 254
ZA - Sudafrica 242
KR - Corea 232
TG - Togo 228
FI - Finlandia 223
EE - Estonia 194
CI - Costa d'Avorio 122
AR - Argentina 106
CA - Canada 105
JO - Giordania 100
BG - Bulgaria 93
PH - Filippine 89
AT - Austria 77
TH - Thailandia 75
SC - Seychelles 74
ID - Indonesia 69
TR - Turchia 46
ES - Italia 44
PL - Polonia 44
TW - Taiwan 44
BE - Belgio 43
EC - Ecuador 42
MX - Messico 42
PK - Pakistan 39
IQ - Iraq 37
UZ - Uzbekistan 37
IR - Iran 33
CO - Colombia 28
GR - Grecia 28
CL - Cile 27
AU - Australia 24
SA - Arabia Saudita 24
NG - Nigeria 23
HR - Croazia 20
MA - Marocco 20
MY - Malesia 17
EG - Egitto 16
LT - Lituania 16
RO - Romania 16
VE - Venezuela 16
CZ - Repubblica Ceca 15
PY - Paraguay 15
LB - Libano 14
AE - Emirati Arabi Uniti 12
ET - Etiopia 12
HU - Ungheria 12
CR - Costa Rica 11
JM - Giamaica 10
TN - Tunisia 10
DZ - Algeria 9
PE - Perù 9
DK - Danimarca 8
KZ - Kazakistan 8
LU - Lussemburgo 8
PT - Portogallo 8
SV - El Salvador 8
BO - Bolivia 7
NP - Nepal 7
OM - Oman 7
AZ - Azerbaigian 6
IL - Israele 6
UY - Uruguay 6
EU - Europa 5
HN - Honduras 5
KE - Kenya 5
MK - Macedonia 5
TT - Trinidad e Tobago 5
LV - Lettonia 4
MD - Moldavia 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
AL - Albania 3
BY - Bielorussia 3
CM - Camerun 3
CY - Cipro 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GH - Ghana 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PS - Palestinian Territory 3
SN - Senegal 3
Totale 44.071
Salva come PNG Salva come JPEG
Città #
Singapore 2.402
Southend 2.169
Fairfield 1.736
Ashburn 1.589
Chandler 1.112
Ho Chi Minh City 1.083
Hanoi 971
Hong Kong 948
San Jose 932
Woodbridge 756
Santa Clara 699
Houston 668
Seattle 662
Wilmington 649
Princeton 558
Cambridge 546
Dong Ket 540
Hefei 463
Bologna 461
Dublin 445
Boardman 428
Beijing 369
Ann Arbor 364
Jacksonville 363
Los Angeles 313
Lauterbourg 297
Bern 238
Council Bluffs 238
Westminster 228
Lomé 227
Nanjing 226
Tokyo 218
New York 207
Padova 199
Dallas 194
Milan 181
Seoul 180
Da Nang 168
Helsinki 167
Berlin 162
Buffalo 141
Haiphong 139
Abidjan 122
Saint Petersburg 105
Shenyang 103
São Paulo 103
Jinan 100
Amman 99
San Diego 95
Florence 93
Munich 92
Rome 91
Sofia 90
Changsha 86
Frankfurt am Main 82
Medford 80
Redondo Beach 79
Turin 76
Hebei 75
Nanchang 73
Shanghai 69
Guangzhou 68
Mülheim 68
Redmond 67
Dearborn 65
Chicago 64
Tianjin 61
London 59
Hải Dương 57
Orem 54
Phoenix 54
Hangzhou 53
Bengaluru 50
Biên Hòa 49
Des Moines 47
Redwood City 47
Zhengzhou 46
Amsterdam 45
The Dalles 44
Bremen 43
Can Tho 42
Nuremberg 41
Vienna 41
Falls Church 38
Mahé 38
Norwalk 38
Olalla 38
Brussels 36
Ninh Bình 36
Brooklyn 35
Denver 35
Johannesburg 35
Falkenstein 34
Jiaxing 34
Mountain View 32
San Francisco 32
Bến Tre 30
Quận Bình Thạnh 30
Turku 30
Montreal 29
Totale 28.094
Salva come PNG Salva come JPEG
Nome #
The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. 359
TACE treatment in hepatocellular carcinoma: what should we do now? 346
Impact of a newly established expert clinical pharmacological advice program based on TDM results in tailoring antimicrobial therapies hospital-wide in a tertiary university hospital: findings after the first-year of implementation 317
Efficacy of radioembolization according to tumor morphology and portal vein thrombosis inintermediate-advanced hepatocellular carcinoma 315
Monofocal hepatocellular carcinoma: How much does size matter? 296
Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study 288
g-hydroxybutyrate as a treatment for alcoholism. 271
Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. 268
Alcol, sindrome feto-alcolica, apparato ematopoietico, muscolo-scheletrico, respiratorio, cute e reni. 260
Beneficial prognostic effects of aspirin in patients receiving sorafenib for hepatocellular carcinoma: A tale of multiple confounders 257
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 252
A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma 244
A novel sodium overload test predicting ascites decompensation in rats with CCl4-induced cirrhosis. 243
Pattern of macrovascular invasion in hepatocellular carcinoma 242
A nomogram-based prognostic model for advanced hepatocellular carcinoma patients treated with sorafenib: A multicenter study 242
Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications 240
Hyperkeratosis of nipple skin during sorafenib treatment 238
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study 236
Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma 235
Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs 234
C-11 Acetate does not enhance usefulness of F-18 FDG PET/CT in differentiating between focal nodular hyperplasia and hepatic adenoma. 229
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma 228
Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study 226
Art in hospital: its impact on the feelings and emotional state of patients admitted to an Internal Medicine Unit. 225
BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. 223
The nutritional status modulates preservation-reperfusion injury in rat fatty liver. 222
Prognostication of the outcome of hepatocellular carcinoma: how to rely on science instead of the art of Nostradamus 222
A novel sodium overload test predicting ascites decompensation in rats with CCL4-induced cirrhosis. 221
Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon 219
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. 219
Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma 218
Combined mechanical and pharmacologic thrombolysis for portal vein thrombosis in liver-graft recipients and in candidates for liver transplantation. 216
Oxidative injury in rat fatty liver exposed to ischemia-reperfusion is modulated by nutritional status. 216
Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group 213
Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatments and outcome. 212
The reduced tolerance of rat fatty liver to ischemia-reperfusion is associated to mitochondrial oxidative injury. 211
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 211
The changing scenario of hepatocellular carcinoma in Italy: an update 209
Long-term beta-blockade shortens Qt interval prolongation in patients with liver cirrhosis 209
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 209
Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20 year multicentre experience. 208
Application of the Intermediate-Stage Subclassification to Patients with Untreated Hepatocellular Carcinoma 208
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA. database 208
Muscle circulation contributes to hyperdynamic circulatory syndrome in advanced cirrhosis. 207
Differential diagnosis between focal nodular hyperplasia and hepatocellular adenoma: Potential role of double tracer PET with 11C-Acetate and 18F-FDG 206
Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma 205
Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment 201
Influence of clinically significant portal hypertension on survival after hepatic resection for hepatocellular carcinoma in cirrhotic patients 200
Metabolic disorders across hepatocellular carcinoma in Italy 200
Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib 199
Cardiac electrophysiological abnormalities in patients with cirrhosis. 199
Basi scientifiche per la definizione delle linee guida in ambito clinico per l’epatocarcinoma. 197
Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma 196
C-type natriuretic peptide (CNP) favours natriuresis in pre-ascitic cirrhotic patients. 193
Daily profile of circulating c-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects. Relationship with renal function. 193
Recent advances in the natural history of hepatocellular carcinoma. 193
Transthoracic electrical bioimpedance: a non-invasive technique for the evaluation of the hemodynamic alterations in patients with liver cirrhosis. 191
Trattamento farmacologico della intossicazione acuta, sindrome post-sbornia e sindrome d’astinenza da alcol. 190
Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice 190
Retrospective analysis of dose–response for HCC lesions treated with 90Y resin microspheres. 190
Surveillance for hepatocellular carcinoma in elderly italian patients with cirrhosis. Effects on cancer staging and patients survival. 190
Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. 188
Insufficienza epatica acuta ed epatite subacuta. 188
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. 188
Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. 188
Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis. 188
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis. 187
Gamma-hydroxybutyric acid plus naltrexone in the treatment of alcoholics resistant to monotherapy. 185
Alfa-fetoprotein in hepatocellular carcinoma (HCC): diagnostic and prognostic role, clinical and biological predictors. Analysis of 1099 patients. 185
Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischemia-reperfusion injury complicated by endotoxemia. 184
Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma 184
Survival and Tolerability of Transarterial Chemoembolization in Greater Versus less than 70 Years of Age Patients with Unresectable Hepatocellular Carcinoma: A Propensity Score Analysis 184
Immunotherapy with checkpoint inhibitors for hepatocellular carcinoma: Where are we now? 184
Alcohol misuse and traffic accidents 181
Ablation and resection for hepatocellular carcinoma within Milan criteria and high alpha-foetoprotein levels 181
QT Interval Correction in Patients with Cirrhosis 181
Telangiectasia as a presenting sign of Graves’ disease. 178
Terlipressin infusion induces ischemia of breast skin in a cirrothic patient with hepatorenal syndrome 177
Suppression of craving for gamma-hydroxybutyric acid by naltrexone administration: three case reports. 176
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma 176
Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib 176
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. 175
Small (≤3cm) Hepatocellular Carcinoma in Cirrhosis: the Role of Double Contrast Agents MR Imaging vs. Multi-Detector Row CT 175
Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma 174
Alcolismo 174
How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. 174
Torsade de pointes” during amiodarone infusion in cirrhotic woman with the prolonged QT interval. 172
Hepatic decompensation is the major driver of death In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. 172
Development and validation of a scoring system that includes corrected QT interval for risk analysis of patients with cirrhosis and gastrointestinal bleeding 172
Overview of prognostic systems for hepatocellular carcinoma and ITA.LI.CA external validation of MESH and CNLC classifications 172
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 171
High risk of hepatocellular carcinoma in anti-HBe positive liver cirrhosis patients developing Lamivudine resistance. 170
Storia naturale dell’epatocarcinoma. 170
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma 169
Is it time to extend criteria for hepatic resection in the treatment of hepatocellular carcinoma? 169
Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. 168
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study. 168
Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with liver cirrhosis 168
Portal vein arterialization increases liver regeneration in acute liver failure induced by extended hepatectomy or toxin administration in the rat 167
Adequate Interval For Hepatocellular Carcinoma Surveillance 167
Totale 20.811
Salva come PNG Salva come JPEG
Categoria #
all - tutte 123.637
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 123.637
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.038 0 0 0 0 0 0 0 0 0 0 0 1.038
2021/20224.643 307 168 267 345 431 244 104 323 197 251 1.273 733
2022/20235.089 511 758 265 597 330 363 178 259 903 125 416 384
2023/20241.571 104 239 113 133 148 283 115 102 111 102 60 61
2024/20255.822 183 904 518 395 1.009 302 385 152 81 428 231 1.234
2025/202615.893 1.425 1.073 1.240 1.040 1.474 840 2.128 691 3.086 1.235 946 715
Totale 44.827